No Data
No Data
12 Health Care Stocks Moving In Thursday's Pre-Market Session
TNF Pharmaceuticals Presents Novel Oral TNF-Alpha Inhibitor At Premier International Conference On Frailty And Sarcopenia
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
TNF Pharmaceuticals Discusses Isomyosamine Progress in Call
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial Of First Oral TNF-Alpha Inhibitor Candidate Isomyosamine For Treatment For Chronic Inflammation Associated With Muscle Loss In Patients Who Undergone Hip Or Femur Fracture Repair Surgery